- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 231/14
Total number of patents in this class: 1158
10-year publication summary
103
|
71
|
93
|
79
|
70
|
76
|
77
|
59
|
46
|
1
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bayer Cropscience AG | 2138 |
66 |
Syngenta Participations AG | 3032 |
60 |
Theravance Biopharma R&D IP, LLC | 517 |
49 |
BASF SE | 20432 |
35 |
BioCryst Pharmaceuticals, Inc. | 176 |
22 |
Takeda Pharmaceutical Company Limited | 2943 |
20 |
Orion Corporation | 595 |
19 |
Syngenta Limited | 482 |
16 |
Sumitomo Chemical Company, Limited | 8988 |
16 |
Activesite Pharmaceuticals, Inc. | 18 |
15 |
AstraZeneca AB | 2958 |
14 |
KalVista Pharmaceuticals Limited | 115 |
14 |
Solvay SA | 1030 |
12 |
sanofi-aventis | 393 |
12 |
Dow AgroSciences LLC | 1238 |
11 |
F. Hoffmann-La Roche AG | 7942 |
10 |
Bayer Intellectual Property GmbH | 2569 |
10 |
Blade Therapeutics, Inc. | 21 |
10 |
Research Triangle Institute | 408 |
10 |
Rezolute, Inc. | 25 |
10 |
Other owners | 727 |